Skip to main content
. 2019 Aug 2;34(5):578–583. doi: 10.1097/HCO.0000000000000647

FIGURE 1.

FIGURE 1

Potential framework for identifying patients without baseline heart failure or established atherosclerotic cardiovascular disease who may benefit from sodium-glucose cotransporter-2 inhibitors. aSaxagliptin and alogliptin. bIncluding neuropathy, retinopathy, or nephropathy. ASCVD, atherosclerotic cardiovascular disease; HbA1c, glycated hemoglobin; NTproBNP, N-terminal probrain natriuretic peptide; SGLT-2, sodium-glucose cotransporter-2; TZD, thiazolidinedione.